News

January 15, 2021January 15, 2021

Silo Pharma, University to Explore Ways of Making MS Therapies More Effective

News

Silo Pharma has entered into a sponsored research agreement with the University of Maryland to develop and explore the potential of a targeted therapy delivery system for multiple sclerosis (MS). ... Read more

January 15, 2021January 15, 2021

Sexual Dysfunction Common in Men with MS, Review Finds

News

Sexual dysfunction affects more than 60% of adult men with multiple sclerosis (MS), according to a review study. The data add to previous findings showing that more than two-thirds ... Read more

January 14, 2021January 14, 2021

New Technique May Help Isolate, Characterize T-cells in MS Research

News

Scientists at the UCLA Broad Stem Cell Research Center have developed a technique able to more efficiently isolate specific T-cells — immune cells involved not only in the fight ... Read more

January 14, 2021January 15, 2021

Public-private Partnership Will Assess Therapy Potential, Effects of CBD

News

Open Book Extracts (OBX) and Case Western Reserve University School of Medicine have partnered to investigate how cannabinoids like CBD affect brain cells, particularly in regard to neuroinflammation, according ... Read more

January 13, 2021January 13, 2021

HTR2A Gene Changes Found Only in Progressive MS May Be New Biomarker

News

Scientists have discovered epigenetic changes in a gene called HTR2A, found only in immune cells isolated from people with secondary progressive multiple sclerosis (SPMS), a study reported. These findings ... Read more

January 13, 2021January 14, 2021

GW Pharma Plans More Clinical Trials for Sativex

News

GW Pharmaceuticals is planning to continue recruiting patients into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as ... Read more

January 12, 2021January 12, 2021

Lemtrada May Slow MS Disease Progression, Long-term Study Suggests

News

Lemtrada (alemtuzumab) may slow the progression of multiple sclerosis (MS) and lower the conversion rate of relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS), a long-term study suggests. The results ... Read more

January 12, 2021January 12, 2021

Helius Provides More Information to FDA About PoNS Device

News

Helius Medical Technologies has submitted its response to the U.S. Food and Drug Administration (FDA)’s request for more information about the company’s application for de novo classification and clearance of ... Read more

January 11, 2021January 11, 2021

Cancer Therapy Seen to Protect Blood-brain Barrier, Ease MS in Mouse Model

News

Imatinib, a cancer treatment, stopped an injury response mechanism of the central nervous system (CNS) from activating, damage to which is a hallmark of multiple sclerosis (MS), an early ... Read more

January 11, 2021January 14, 2021

BioNTech Vaccine Treats MS in Mice Without Dampening Immune System

News

BioNTech’s experimental non-inflammatory vaccine — designed to dampen the abnormal immune responses seen in multiple sclerosis (MS) against myelin — delayed the onset and lessened the severity of symptoms ... Read more

January 8, 2021January 8, 2021

Study: Past Long-term DMT Use Tapers Risk of Current MS Progression

News

Long-term use of disease-modifying therapies (DMTs) in people with relapsing-remitting multiple sclerosis (RRMS) has a beneficial cumulative effect compared to shorter treatments, delaying the development of irreversible disability and ... Read more

January 8, 2021January 8, 2021

Target Tissues of Immune Attacks Too Often Ignored in Research, Study Says

News

To fully understand autoimmune diseases like multiple sclerosis (MS), it is necessary to study not just the immune system, but also the tissue that the immune system is attacking, ... Read more

January 7, 2021January 7, 2021

CXCL13, Inflammatory Marker, May Be Good at Predicting Likely MS Activity

News

CXCL13, an inflammatory biomarker, may be a good marker of likely future disease activity in people with multiple sclerosis (MS), a study suggests. The study, “Intrathecally produced CXCL13: A predictive ... Read more

January 7, 2021January 8, 2021

Obesity, High BMI Linked to Greater MS Risk, Autoimmune Activity

News

Obesity and a higher body mass index (BMI) are associated with both increased multiple sclerosis (MS) risk and harmful autoimmune activity that is induced by leptin, a hormone secreted ... Read more

January 6, 2021January 6, 2021

Less Sunlight Means More Risk of Relapse, Disability, Studies Assert

News

Reduced exposure to sunlight, previously reported as a risk factor for developing multiple sclerosis (MS), also seems to increase the risk for relapse and worsening disability, data from two ... Read more

January 6, 2021January 6, 2021

MSAA Hosting 8th Webinar on COVID-19 and MS

News

The Multiple Sclerosis Association of America (MSAA) is hosting a webinar in which experts will discuss the COVID-19 pandemic and its impact on multiple sclerosis (MS). The webinar, “What ... Read more

January 5, 2021January 5, 2021

Sobek Prize Given Physician-scientist for Work in Progressive MS

News

The 2020 Sobek Research Prize has been given to Alan J. Thompson, MD, a physician scientist with University College London, for his pioneering work in progressive multiple sclerosis (MS), ... Read more

January 5, 2021January 5, 2021

Myelin Ceramides Altered in MS, Study Finds

News

Levels of myelin sheath components called ceramides are altered in the blood of people with multiple sclerosis (MS) and may be linked with retinal degeneration and physical disability, a ... Read more

January 4, 2021January 4, 2021

Mentally Overestimating Motor Tasks May Cause Cognitive Fatigue in MS

News

People with multiple sclerosis (MS) tend to mentally overestimate the time required to complete a short walking activity, causing cognitive fatigue that may affect their quality of life, a ... Read more

January 4, 2021January 5, 2021

Boosting Cholesterol Recycling in Brain Facilitates Myelin Repair, Study Says

News

New research in mice suggests that poor recycling of cholesterol in the brain impairs the repair of myelin, the protective coat surrounding nerve cells that is lost in multiple ... Read more

December 31, 2020December 31, 2020

MS Risk May Be Higher for Children of Diabetic Mothers, Study Suggests

News

Children of diabetic mothers may be at more risk of developing multiple sclerosis (MS), a Danish national study suggests. The study, “Maternal diabetes and risk of multiple sclerosis in the ... Read more

December 29, 2020January 4, 2021

Plegridy as Intramuscular Injection for RRMS Approved in Europe

News

The European Commission (EC) has approved a new, intramuscular formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing-remitting multiple sclerosis (RRMS). This new mode of administration — in ... Read more

December 22, 2020December 22, 2020

MSAA Asks Patients to Take Survey Into Opinions on Clinical Trials

News

People with multiple sclerosis (MS) are encouraged to complete a survey aimed at understanding the experiences and expectations of those with a chronic illness who have either participated in ... Read more

December 21, 2020December 21, 2020

Dosing Finishes in Trial of NurOwn Cell Therapy for Progressive MS

News

Patient dosing has finished in a Phase 2 clinical trial testing NurOwn, BrainStorm Cell Therapeutics’ investigational cell-based therapy for people with progressive multiple sclerosis (MS), the company announced. The trial’s ... Read more

December 21, 2020December 21, 2020

Kesimpta Available Through AllianceRx for US Patients With Relapsing MS

News

Kesimpta (ofatumumab), the first self-administered B-cell therapy to treat relapsing forms of multiple sclerosis (MS), is now available via AllianceRx Walgreens Prime, one of the largest specialty and home ... Read more

December 18, 2020December 18, 2020

Primary Headaches Prevalent in MS, Research Reveals

News

The prevalence of primary headaches — those with no clear cause — is high among patients with multiple sclerosis (MS), a new study suggests. Clinical screening of headache among ... Read more

December 18, 2020December 21, 2020

Mayzent Aids Cognitive Processing Speed in SPMS Patients, Trial Suggests

News

Mayzent (siponimod) significantly improved cognitive processing speed in people with secondary progressive multiple sclerosis (SPMS) compared with a placebo, according to additional analyses of two-year data from the EXPAND Phase ... Read more

December 17, 2020December 17, 2020

Restoring Neuregulin-1 beta 1 Protein Levels May Help Halt MS Progression

News

The levels of a protein called Neuregulin-1 beta 1 (Nrg-1beta1) decline with the onset and progression of multiple sclerosis (MS), a new study suggests. The findings support the potential ... Read more

December 17, 2020December 17, 2020

Progressive MS Patients Urged to Enroll in Phase 3 Trials of Tolebrutinib

News

Investigators are looking for people with progressive forms of multiple sclerosis (MS) to participate in two Phase 3 clinical trials assessing the safety and effectiveness of tolebrutinib (SAR442168), an ... Read more

December 16, 2020December 16, 2020

US Patients Urged to Enroll in STEP for MS Trial Assessing 2 Exercise Programs

Covid-19, News

Adults with mild to moderate multiple sclerosis (MS) are being urged to participate in a new clinical trial — STEP for MS — that will assess the impact of ... Read more

December 16, 2020December 16, 2020

Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial

News

Lesser or stable disability over two years was evident in most progressive multiple sclerosis (MS) patients given a stem cell treatment in a small Phase 1 clinical trial, supporting ... Read more

December 15, 2020December 15, 2020

Study Seeks to Better Understand How MS Affects Memory

News

A new research project will seek to better understand the biological processes that drive memory problems in people with multiple sclerosis (MS), as a better understanding of these processes ... Read more

December 15, 2020December 15, 2020

FDA Approves Shorter Infusion Time for MS Therapy Ocrevus

News

The U.S. Food and Drug Administration has approved a shorter infusion time of Ocrevus (ocrelizumab) for treating relapsing or primary progressive multiple sclerosis (MS). Infusion refers to the slow ... Read more

December 14, 2020December 15, 2020

Sanofi Enrolling for 2 GEMINI Trials Testing Tolebrutinib vs. Aubagio for Relapsing MS

Covid-19, News

Two global Phase 3 clinical trials, both comparing Sanofi Genzyme’s investigational tolebrutinib with its approved therapy Aubagio, are enrolling a total of 1,800 people with relapsing multiple sclerosis (MS), ... Read more

December 14, 2020December 14, 2020

Ublituximab Superior to Aubagio at Lowering Relapse Rates, Phase 3 Data Show

News

Ublituximab, an investigational anti-CD20 antibody, outperformed Aubagio (teriflunomide) in lowering the frequency of relapses among people with active, relapsing forms of multiple sclerosis (MS), according to top-line data from ... Read more

December 11, 2020December 11, 2020

MS Patients Urged to Enroll in Clinical Trial Assessing Chronic Fatigue Treatments

News

Adults with multiple sclerosis (MS) are being urged to enroll in a new clinical trial — now recruiting in Washington and Michigan states — that aims to assess the ... Read more

December 11, 2020December 11, 2020

Inflammatory Environment in MS Impairs Myelin Debris-clearing by Immune Cells

News

The pro-inflammatory environment characteristic of multiple sclerosis (MS) reduces the levels of PPAR-gamma — a receptor protein whose activation dampens inflammation — and impairs myelin processing in immune cells that ... Read more

December 10, 2020December 10, 2020

Children With MS Recover Better From Relapses Than Adults, Study Suggests

News

Despite having more severe first and second relapses, children with relapsing-remitting multiple sclerosis (RRMS) tend to recover better than adults with the disease, according to a study. Better recovery ... Read more

December 10, 2020December 10, 2020

Stem Cell Transplant Reduces Relapses and Disability in RRMS, Study Suggests

News

Autologous hematopoietic stem cell transplant (AHSCT) induces a reduction in relapse rate and physical disability in patients with relapsing-remitting multiple sclerosis (RRMS) who respond inadequately to other treatments, a ... Read more